Abstract: Use of decellularized plant tissues as scaffolds for producing edible animal tissue are disclosed herein. Particularly, decellularized plant tissues are used as scaffolds for animal cells to allow growth and differentiation it animal tissue. The edible animal tissue can be dried such as in a beef jerky form for human consumption.

Abstract: Provided herein are enzymatically decellularized cells, and methods of producing said cells, that can be used in a scaffold. The scaffolds featured herein are biocompatible and can comprise decellularized cells that have been modified to express a bioactive agent or molecule.

Abstract: Decellularized plant tissues and the use of these plant tissues as scaffolds are disclosed herein. Particularly, decellularized plant tissues are functionalized such to allow for human cell adhesion, thereby allowing for their use as scaffolds for human cells. These scaffolds can then be used in a number of applications/markets, including as research tools for tissue engineering, regenerative medicine, and basic cellular biology.

Abstract: An in vitro meat having non-decellularized leaf scaffold and a method for producing an in vitro meat using non-decellularized leaf scaffold are described herein. The method includes preparing a non-decellularized plant leaf and incubating the leaf in a cell culture media to obtain a non-decellularized leaf scaffold; seeding the leaf scaffold with a population of muscle cells to obtain a leaf scaffold adhered population of muscle cells; and growing the leaf scaffold adhered population of muscle cells in cell culture media thereby obtaining the in vitro meat.

Abstract: Provided herein are enzymatically decellularized cells, and methods of producing said cells, that can be used in a scaffold. The scaffolds featured herein are biocompatible and can comprise decellularized cells that have been modified to express a bioactive agent or molecule.

Abstract: The present disclosure relates to the field of tissue mapping and ablation. Specifically, the present disclosure relates to expandable medical devices for identifying and treating local anatomical abnormalities within a body lumen. More specifically, the present disclosure relates to systems and methods of focal treatment for overactive bladders.

Abstract: Provided herein are enzymatically decellularized cells, and methods of producing said cells, that can be used in a scaffold. The scaffolds featured herein are biocompatible and can comprise decellularized cells that have been modified to express a bioactive agent or molecule.

Abstract: The present invention relates, in part, to sutures which promote wound closure and/or healing. In particular, the present invention provides fibrin microthread sutures that mimic the mechanical behavior of a target tissue thereby reducing, for example, scarring, inflammation, and cell death at the ligature site, including monofilament sutures.

Abstract: The present invention relates, in part, to sutures which promote wound closure and/or healing. In particular, the present invention provides fibrin microthread sutures that mimic the mechanical behavior of a target tissue thereby reducing, for example, scarring, inflammation, and cell death at the ligature site, including monofilament sutures.

Abstract: In part, the invention described herein relates generally to sutures and uses thereof in surgical procedures, including fibrin microthread sutures for surgical procedures that provide one or more of lower inflammation, reduced fibrosis, reduced scarring, and fast absorption in the host tissue.

Abstract: The present disclosure relates to the field of tissue mapping and ablation. Specifically, the present disclosure relates to expandable medical devices for identifying and treating local anatomical abnormalities within a body lumen. More specifically, the present disclosure relates to systems and methods of focal treatment for overactive bladders.

Abstract: Compositions that include microthreads are provided. The compositions can be fully or partially encased in a sleeve along at least a portion of their length and can include biological cells and, optionally, therapeutic agents. Also provided are methods for using the compositions to repair or ameliorate damaged or defective tissue, including cardiovascular tissue (e.g., the myocardium).

Abstract: The invention is directed to a device and method to prevent migration of Human Mesenchymal Stem Cells (hMSCs) from a delivery site while allowing communication between the stem cells and native cardiomyocytes. The device is characterized by scaffold pore size, fiber diameter and biomaterial selection. The invention includes a two part polyurethane scaffold that prevents migration of stem cells, allows gap junction formation through pores and is packaged for minimally invasive delivery.

Abstract: A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in the subject. This invention further provides related articles of manufacture and methods.

Abstract: The present invention provides methods and compositions relating to the labeling of target cells with nanometer scale fluorescent semiconductors referred to as quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been genetically engineered to express, for example, a hyperpolarization-activated cyclic nucleotide-gated (“HCN”) channel and administered to a subject to create a biological pacemaker. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks.

Abstract: The invention is directed to a device and method to prevent migration of Human Mesenchymal Stem Cells (hMSCs) from a delivery site while allowing communication between the stem cells and native cardiomyocytes. The device is characterized by scaffold pore size, fiber diameter and biomaterial selection. The invention includes a two part polyurethane scaffold that prevents migration of stem cells, allows gap junction formation through pores and is packaged for minimally invasive delivery.

Abstract: The present invention provides methods and compositions relating to the production of stem cells, derived from dedifferentiated fibroblasts, and the use of such stem cells for treatment of a variety of different disorders and conditions. The invention is based on the surprising discovery that a population of stem cells, capable of differentiating into a variety of different cell types, can be generated by culturing fibroblasts under selective culture conditions.

Abstract: Compositions that include microthreads are provided. The compositions can be fully or partially encased in a sleeve along at least a portion of their length and can include biological cells and, optionally, therapeutic agents. Also provided are methods for using the compositions to repair or ameliorate damaged or defective tissue, including cardiovascular tissue (e.g., the myocardium).

Abstract: The present invention relates to methods and compositions for stimulating the proliferation of cardiomyocytes for enhancement of cardiac repair. The invention is based on the discovery that upon contact with stem cells, or conditioned media derived from said stem cells, terminally differentiated cardiomyocytes can be stimulated to enter the cell cycle. Additionally, scaffolds capable of attracting stem cells to the area of implantation have been shown to induce cardiomyocyte proliferation. The present invention further relates to the discovery that the Wnt-5A ligand, which binds to the frizzled receptor (fz), functions to stimulate cardiomyocyte proliferation. The methods and compositions of the invention may be used in the treatment of cardiac disorders including, but not limited to, myocardial dysfunction or infarction.

Abstract: A method of assisting recovery of an injury site of the central nervous system (CNS) or treating a disease includes providing a therapeutic dose of X-ray radiation to a target volume through an array of parallel microplanar beams. The dose to treat CNS injury temporarily removes regeneration inhibitors from the irradiated site. Substantially unirradiated cells surviving between beams migrate to the in-beam portion and assist recovery. The dose may be staggered in fractions over sessions using angle-variable intersecting microbeam arrays (AVIMA). Additional doses are administered by varying the orientation of the beams. The method is enhanced by injecting stem cells into the injury site. One array or the AVIMA method is applied to ablate selected cells in a target volume associated with disease for palliative or curative effect. Atrial fibrillation is treated by irradiating the atrial wall to destroy myocardial cells while continuously rotating the subject.